Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...

Resurgence Publishes New Resource Clarifying the Difference Between Anthem and Blue Cross Blue Shield

Resurgence Alcohol & Drug Rehab Riverside has published a new educational resource designed to clarify the differences between Anthem and Blue Cross Blue Shield, two major health insurance providers ...

New group of potential diabetes drugs with fewer side effects can reprogram insulin-resistant cells to be healthier

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...
TipRanks on MSN

Takeda, Protagonist Therapeutics submit rusfertide New Drug Application to FDA

Takeda (TAK) and Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA seeking approval of rusfertide for ...